JAK1/2

View All

JAK Inhibitors market | JAK inhibitors | JAKs | Janus Kinase
JAK Inhibitors Market

JAK inhibitors also termed “Jakinibs,” work by inhibiting the activity and response of one or more Janus kinase enzymes. These inhibitors function against the Janus kinases, a group of four proteins that includes JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). These proteins control inflammation by triggering intra...

Find More

Entasis
AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal

AstraZeneca dragout Entasis files to fund antibiotic phase 3 for USD 86 Million IPO Massachusetts-based Entasis Therapeutics has spun out to raise up to USD 86 Million through an IPO. The AstraZeneca spinout is attempting to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams. In 2015, ...

Find More